Phreesia (NYSE:PHR) SVP Amy Beth Vanduyn Sells 639 Shares

Phreesia, Inc. (NYSE:PHR) SVP Amy Beth Vanduyn sold 639 shares of the stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $22.36, for a total value of $14,288.04. Following the completion of the transaction, the senior vice president directly owned 111,840 shares of the company’s stock, valued at approximately $2,500,742.40. The trade was a 0.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Amy Beth Vanduyn also recently made the following trade(s):

• On Tuesday, September 16th, Amy Beth Vanduyn sold 1,762 shares of Phreesia stock. The shares were sold at an average price of $23.28, for a total value of $41,019.36.

Phreesia Stock Performance

Shares of NYSE:PHR opened at $23.11 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.12 and a quick ratio of 2.12. The business’s fifty day moving average price is $25.92 and its two-hundred day moving average price is $25.97. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $32.76. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of -55.02 and a beta of 0.68.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Thursday, September 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.08. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The company had revenue of $117.26 million during the quarter, compared to analysts’ expectations of $116.39 million. During the same period last year, the business earned ($0.03) earnings per share. The business’s revenue was up 14.9% on a year-over-year basis. Phreesia has set its FY 2026 guidance at EPS. As a group, analysts predict that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Institutional Trading of Phreesia

Hedge funds and other institutional investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Phreesia by 108.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company’s stock worth $67,606,000 after purchasing an additional 1,377,904 shares during the last quarter. Loomis Sayles & Co. L P bought a new position in Phreesia in the 2nd quarter valued at $34,162,000. American Century Companies Inc. increased its stake in shares of Phreesia by 3,741.9% in the 1st quarter. American Century Companies Inc. now owns 983,440 shares of the company’s stock valued at $25,137,000 after buying an additional 957,842 shares during the period. Nuveen LLC bought a new stake in shares of Phreesia during the first quarter worth $14,206,000. Finally, Champlain Investment Partners LLC lifted its stake in shares of Phreesia by 20.0% during the first quarter. Champlain Investment Partners LLC now owns 2,946,489 shares of the company’s stock valued at $75,312,000 after acquiring an additional 490,340 shares during the period. Institutional investors and hedge funds own 92.10% of the company’s stock.

Wall Street Analysts Forecast Growth

PHR has been the topic of a number of recent analyst reports. Stephens restated an “overweight” rating and issued a $32.00 price target on shares of Phreesia in a research report on Wednesday, September 3rd. Needham & Company LLC boosted their target price on Phreesia from $29.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, September 5th. Mizuho assumed coverage on Phreesia in a research report on Wednesday, August 27th. They set an “outperform” rating and a $36.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Phreesia in a report on Wednesday, October 8th. Finally, Truist Financial boosted their price objective on Phreesia from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Phreesia currently has a consensus rating of “Moderate Buy” and an average price target of $33.85.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.